The customer reported via phone call that they were hospitalized for high blood glucose and diabetic ketoacidosis on (b)(6) 2022.Blood glucose reading was 220 mg/dl at the time of call.The customer stated they became unresponsive from their high blood glucose.Customer reported symptoms like abdominal pain, headache, fever, dizziness.The customer was treated with insulin drip.Troubleshooting was performed and the customer will continue to use the device.
|
(b)(4).Medtronic, inc.(medtronic) is submitting this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information in the time allotted and has provided as much information as is available to the company as of the submission date this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employees caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any "defects" or has "malfunctioned".These words are included in the fda 3500a form and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.Medtronic objects to the use of these words and others like it because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.The information that provided with the initial report was incorrect.The correct information related health effect clinical and impact code has been updated in h6 section.
|